These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

316 related items for PubMed ID: 31366251

  • 1. Transitioning from oral risperidone or paliperidone to once-monthly paliperidone palmitate: a real-world analysis among Veterans Health Administration patients with schizophrenia who have had at least one prior hospitalization.
    El Khoury A, Patel C, Huang A, Wang L, Bashyal R.
    Curr Med Res Opin; 2019 Dec; 35(12):2159-2168. PubMed ID: 31366251
    [Abstract] [Full Text] [Related]

  • 2. Health Outcomes Among Patients Diagnosed with Schizophrenia in the US Veterans Health Administration Population Who Transitioned from Once-Monthly to Once-Every-3-Month Paliperidone Palmitate: An Observational Retrospective Analysis.
    Patel C, El Khoury A, Huang A, Wang L, Baser O, Joshi K.
    Adv Ther; 2019 Oct; 36(10):2941-2953. PubMed ID: 31396809
    [Abstract] [Full Text] [Related]

  • 3. Healthcare Resource Utilization and Costs Among Patients With Schizophrenia Switching From Oral Risperidone/Paliperidone to Once-Monthly Paliperidone Palmitate: A Veterans Health Administration Claims Analysis.
    Patel C, Khoury AE, Huang A, Wang L, Bashyal R.
    Curr Ther Res Clin Exp; 2020 Oct; 92():100587. PubMed ID: 32714469
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Paliperidone Palmitate 3-Monthly Versus 1-Monthly Injectable in Patients With Schizophrenia With or Without Prior Exposure to Oral Risperidone or Paliperidone: A Post Hoc, Subgroup Analysis.
    Mathews M, Pei H, Savitz A, Nuamah I, Hough D, Alphs L, Gopal S.
    Clin Drug Investig; 2018 Aug; 38(8):695-702. PubMed ID: 29882073
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Real-world outcomes post-transition to once-every-3-months paliperidone palmitate in patients with schizophrenia within US commercial plans.
    Emond B, El Khoury AC, Patel C, Pilon D, Morrison L, Zhdanava M, Lefebvre P, Tandon N, Joshi K.
    Curr Med Res Opin; 2019 Mar; 35(3):407-416. PubMed ID: 30556739
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Real-world adherence and economic outcomes associated with paliperidone palmitate versus oral atypical antipsychotics in schizophrenia patients with substance-related disorders using Medicaid benefits.
    Joshi K, Lafeuille MH, Kamstra R, Tiggelaar S, Lefebvre P, Kim E, Yue Y, Tandon N.
    J Comp Eff Res; 2018 Feb; 7(2):121-133. PubMed ID: 28809128
    [Abstract] [Full Text] [Related]

  • 15. Baseline characteristics and treatment patterns of patients with schizophrenia initiated on once-every-three-months paliperidone palmitate in a real-world setting.
    Joshi K, Lafeuille MH, Brown B, Wynant W, Emond B, Lefebvre P, Tandon N.
    Curr Med Res Opin; 2017 Oct; 33(10):1763-1772. PubMed ID: 28741387
    [Abstract] [Full Text] [Related]

  • 16. Treatment patterns and Medicaid spending in comorbid schizophrenia populations: once-monthly paliperidone palmitate versus oral atypical antipsychotics.
    Kamstra R, Pilon D, Lefebvre P, Emond B, Joshi K.
    Curr Med Res Opin; 2018 Aug; 34(8):1377-1388. PubMed ID: 29452492
    [Abstract] [Full Text] [Related]

  • 17. Treatment Patterns, Health Care Resource Utilization, and Spending in Medicaid Beneficiaries Initiating Second-generation Long-acting Injectable Agents Versus Oral Atypical Antipsychotics.
    Pilon D, Tandon N, Lafeuille MH, Kamstra R, Emond B, Lefebvre P, Joshi K.
    Clin Ther; 2017 Oct; 39(10):1972-1985.e2. PubMed ID: 28919292
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Adherence, Persistence, Readmissions, and Costs in Medicaid Members with Schizophrenia or Schizoaffective Disorder Initiating Paliperidone Palmitate Versus Switching Oral Antipsychotics: A Real-World Retrospective Investigation.
    Dickson MC, Nguyen MM, Patel C, Grabich SC, Benson C, Cothran T, Skrepnek GH.
    Adv Ther; 2023 Jan; 40(1):349-366. PubMed ID: 36348142
    [Abstract] [Full Text] [Related]

  • 20. The Impact of Once-Monthly Paliperidone Palmitate on Healthcare Utilization Among Patients With Schizophrenia Treated in an Integrated Healthcare System: A Retrospective Mirror-Image Study.
    Mahabaleshwarkar R, Lin D, Fishman J, Blair T, Hetherington T, Palmer P, Patel C, Benson C, Joshi K, Krull C, Tcheremissine OV.
    Adv Ther; 2021 Apr; 38(4):1958-1974. PubMed ID: 33704681
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.